Xtant Medical Holdings (FRA:XMS) Cyclically Adjusted Revenue per Share: €15.27 (As of Mar. 2026)


FRA:XMS Xtant Medical Holdings Inc FRA:XMS
27 GF Score
Price €0.36
GF Value €0.53
! 4 Warning Signs
View Full Analysis

What is Xtant Medical Holdings Cyclically Adjusted Revenue per Share?

Xtant Medical Holdings FRA:XMS +7.14% 27 Cyclically Adjusted Revenue per Share is €15.27 as of Mar. 2026. GuruFocus rates FRA:XMS with a GF Score™ of 27/100 and a GF Value™ of €0.53. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xtant Medical Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was €0.129. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €15.27 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Xtant Medical Holdings's average Cyclically Adjusted Revenue Growth Rate was -36.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -23.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Xtant Medical Holdings was -6.20% per year. The lowest was -23.60% per year. And the median was -14.10% per year.

As of today (2026-07-12), Xtant Medical Holdings's current stock price is €0.36. Xtant Medical Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €15.27. Xtant Medical Holdings's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xtant Medical Holdings was 0.09. The lowest was 0.01. And the median was 0.02.


Xtant Medical Holdings  (FRA:XMS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xtant Medical Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.36/15.27
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xtant Medical Holdings was 0.09. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xtant Medical Holdings Cyclically Adjusted Revenue per Share Related Terms


Xtant Medical Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xtant Medical Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xtant Medical Holdings Cyclically Adjusted Revenue per Share Chart

Xtant Medical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.79 42.94 36.23 29.78 17.56

Xtant Medical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.50 20.97 20.31 17.56 15.27

FRA:XMS vs POSC, LUNG, MDAI: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Xtant Medical Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xtant Medical Holdings Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:XMS
27GF Score
Xtant Medical Holdings Inc FRA:XMS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xtant Medical Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xtant Medical Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.129/330.2130*330.2130
=0.129

Current CPI (Mar. 2026) = 330.2130.

Xtant Medical Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 18.800 241.018 25.757
201609 20.095 241.428 27.485
201612 19.062 241.432 26.072
201703 13.710 243.801 18.569
201706 12.543 244.955 16.909
201709 10.887 246.819 14.565
201712 10.705 246.524 14.339
201803 1.930 249.554 2.554
201806 1.217 251.989 1.595
201809 1.116 252.439 1.460
201812 1.210 251.233 1.590
201903 1.116 254.202 1.450
201906 1.019 256.143 1.314
201909 1.077 256.759 1.385
201912 1.152 256.974 1.480
202003 1.015 258.115 1.299
202006 0.707 257.797 0.906
202009 0.899 260.280 1.141
202012 0.149 260.474 0.189
202103 0.130 264.877 0.162
202106 0.143 271.696 0.174
202109 0.135 274.310 0.163
202112 0.142 278.802 0.168
202203 0.135 287.504 0.155
202206 0.166 296.311 0.185
202209 0.157 296.808 0.175
202212 0.133 296.797 0.148
202303 0.154 301.836 0.168
202306 0.171 305.109 0.185
202309 0.173 307.789 0.186
202312 0.190 306.746 0.205
202403 0.197 312.332 0.208
202406 0.214 314.175 0.225
202409 0.186 315.301 0.195
202412 0.216 315.605 0.226
202503 0.212 319.799 0.219
202506 0.207 322.561 0.212
202509 0.188 324.800 0.191
202512 0.184 324.054 0.187
202603 0.129 330.213 0.129

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €15.27 mean?
Xtant Medical Holdings (FRA:XMS) has a Cyclically Adjusted Revenue per Share of €15.27 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xtant Medical Holdings and its competitors.
Is Xtant Medical Holdings' Cyclically Adjusted Revenue per Share too high?
Xtant Medical Holdings' current Cyclically Adjusted Revenue per Share is €15.27. Overall, Xtant Medical Holdings has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' Cyclically Adjusted Revenue per Share compare to POSC and LUNG?
Xtant Medical Holdings' Cyclically Adjusted Revenue per Share of €15.27 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xtant Medical Holdings and its competitors. Xtant Medical Holdings's current Cyclically Adjusted Revenue per Share is €15.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Xtant Medical Holdings (FRA:XMS) has a current Cyclically Adjusted Revenue per Share of €15.27. The stock's GF Value™ is €0.53, compared to a current price of €0.36 — trading 32.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €15.27. Xtant Medical Holdings' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xtant Medical Holdings (FRA:XMS), the current Cyclically Adjusted Revenue per Share is €15.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xtant Medical Holdings (FRA:XMS) Overvalued in 2026?

Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued. The current stock price of €0.36 is trading 32.1% below its estimated GF Value™ of €0.53.

Key valuation signals for FRA:XMS:

  • Cyclically Adjusted Revenue per Share: €15.27
  • GF Value™: €0.53 vs. price of €0.36 (32.1% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the FRA:XMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xtant Medical Holdings Business Description

Other Exchanges XTNT:USA
Address 664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
27GF Score

Get the complete analysis for FRA:XMS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.36
Price
€0.53
GF Value